ProCE Banner Activity

Guidance for Diagnosing and Managing Tardive Dyskinesia

Clinical Thought

Even mild tardive dyskinesia can have a severe impact on patients’ lives, making early identification and adequate treatment paramount to preserving quality of life. In this clinical commentary, Christoph U. Correll, MD, provides valuable information on differential diagnosis and treatment individualization for patients with tardive dyskinesia.

Released: June 08, 2023

Share

Faculty

Christoph U. Correll

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Berlin, Germany

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by an educational grant from Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

Disclosure

Primary Author

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Berlin, Germany

Christoph U. Correll, MD: consultant/advisor/speaker: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, Intra-Cellular Therapies, Janssen/Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedinCell, Merck, MindPax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Viatris; researcher: Janssen, Takeda; stock/stock options: Cardio Diagnostics, LB Pharma, MindPax, Quantic.